US0463531089 - ADR - Premarket: 66.36 +0.83 (+1.27%)
NASDAQ:AZN (1/27/2023, 7:00:00 PM)-0.46 (-0.7%)
|GICS Sector||Health Care|
|Earnings (Last)||11-10 2022-11-10/bmo||Earnings (Next)||N/A N/A|
|Ins Owners||N/A||Inst Owners||16.86%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire and currently employs 83,100 full-time employees. The company went IPO on 2007-09-21. The firm focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 179 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia. The company is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.
ASTRAZENECA PLC-SPONS ADR
1 Francis Crick Avenue
Cambridge CAMBRIDGESHIRE CB2 0AA
CEO: Pascal Soriot
This vaccine candidate could be approved in newborns and infants later this year.
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
These are the dividend stocks to buy for a regular income stream and potential capital gains as these stocks trade at attractive valuations.
The FDA announced Thursday that Evusheld, a COVID-19 antibody therapy developed by AstraZeneca (AZN), is no longer authorized in the U.S. due to lack of efficacy. Read the full story here.
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook.
Here you can normally see the latest stock twits on AZN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.